








RESEARCH PAPER



The crystal structure of the toxin EspC from enteropathogenic *Escherichia coli* reveals the mechanism that governs host cell entry and cytotoxicity

Akila U. Pilapitiya ^a, Lilian Hor ^a, Jing Pan^a, Lakshmi C. Wijeyewickrema ^a, Robert N. Pike ^a,
Denisse L. Leyton ^b, Jason J Paxman ^a, and Begoña Heras ^a

^aDepartment of Biochemistry and Chemistry, La Trobe Institute for Molecular Science, School of Agriculture, Biomedicine and Environment, La Trobe University, Bundoora, Australia; ^bResearch School of Biology, Australian National University, Canberra, Australia

ABSTRACT

Enteropathogenic *E. coli* (EPEC) is a significant cause of diarrhea, leading to high infant mortality rates. A key toxin produced by EPEC is the EspC autotransporter, which is regulated alongside genes from the locus of enterocyte effacement (LEE), which collectively result in the characteristic attaching and effacing lesions on the intestinal epithelium. In this study, we present the crystal structure of the EspC passenger domain (α^{EspC}) revealing a toxin comprised a serine protease attached to a large β -helix with additional subdomains. Using various modified EspC expression constructs, alongside type III secretion system-mediated cell internalization assays, we dissect how the α^{EspC} structural features enable toxin entry into the intestinal epithelium to cause cell cytotoxicity.

ARTICLE HISTORY

Received 3 January 2025
Revised 18 February 2025
Accepted 18 March 2025

KEYWORDS

Enteropathogenic *E. coli*;
autotransporter protein;
serine protease; toxins;
bacterial infections; secretion
system; diarrhoea

Introduction

Diarrheal diseases, including dysentery, pose significant health problems, especially in developing countries, where they cause over 1.3 million deaths annually among children under five and contribute to substantial healthcare costs.^{1–3} Pathogenic *Escherichia coli* and *Shigella* are two major enteric pathogens responsible for these diseases. A critical factor that increases the pathogenicity of these diarrheal pathogens is the secretion of high molecular weight toxins known as serine protease autotransporters of *Enterobacteriaceae* (SPATEs). SPATEs are categorized into two classes: class 1, which damage the intestinal epithelium and class 2, which facilitate bacterial colonization through mechanisms such as mucin degradation and modulation of the immune response.^{4–6}


SPATEs are part of the largest family of secreted and outer membrane proteins from Gram-negative bacteria, known as autotransporters.^{7,8} Autotransporters form the type V secretion pathway and share a common architecture that allows them to facilitate their own secretion. This includes an N-terminal

signal peptide for transport into the periplasm and a C-terminal translocator domain that forms a pore in the outer membrane, allowing the secretion of a central functional passenger domain to the bacterial surface.^{9–11} Notably, the BAM complex is required for insertion of the autotransporter translocator domain into the outer membrane.¹²

SPATE passenger domains, as revealed by experimental structures, exhibit high structural conservation, with an N-terminal trypsin-like serine protease domain (subdomain-1/SD1), followed by an extended right-handed 3-stranded β -helix.^{5,9} Loop extensions from the β -helix can form two subdomains (SD2–3). After transport to the bacterial surface, the SPATE passengers are released into the extracellular environment.

Many of the class 1 SPATEs enter human tissue to cause cell rounding and, ultimately, disruption to the intestinal epithelium and inflammation, contributing to symptoms of enteric infections such as diarrhea. Plasmid encoded toxin (Pet) from enteroaggregative *E. coli* (EAEC) is the most comprehensively studied of these class 1 SPATEs.¹³ The

CONTACT Begoña Heras  b.heras@latrobe.edu.au; Jason Paxman  j.paxman@latrobe.edu.au  Department of Biochemistry and Chemistry, La Trobe Institute for Molecular Science, La Trobe University, Kingsbury Drive, Bundoora VIC 3086, Australia

 Supplemental data for this article can be accessed online at <https://doi.org/10.1080/19490976.2025.2483777>

© 2025 The Author(s). Published with license by Taylor & Francis Group, LLC.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/4.0/>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The terms on which this article has been published allow the posting of the Accepted Manuscript in a repository by the author(s) or with their consent.

Pet subdomain-2 (SD2) interacts with the epithelial receptor cytokeratin-8 to enter cells by receptor-mediated endocytosis, where it enters the cell cytosol via trafficking in clathrin-coated vesicles.^{14,15} Upon entry into the cytosol, the Pet protease subdomain cleaves actin-associated fodrin to cause cellular rounding and disruption to the epithelium.¹⁶

The SPATE class 1 enterotoxin EspC is associated with enteropathogenic *E. coli* (EPEC), a major cause of severe and sometimes fatal diarrhea in infants, particularly in developing countries.¹⁷ Since EPEC lacks the ability to produce Shiga toxins, heat-labile and heat-stable enterotoxins,¹⁷ EspC is considered a significant toxin in this pathogen. EspC is encoded in the second pathogenicity island (PAI) of EPEC,¹⁸ but its expression is regulated by the Ler regulator together with genes in the enterocyte effacement (LEE) pathogenicity island. The latter is responsible for intimate colonization, enterocyte effacement, and pedestal formation leading to the characteristic lesions of EPEC infection.¹⁹ The LEE pathogenicity island exerts these effects through the injection of effectors into host cells via a type III protein secretion system (T3SS) encoded on the LEE.^{20,21}

The secreted passenger domain of EspC (α^{EspC}) plays a central role in the cytopathic effects on intestinal epithelium during EPEC infection. Similar to Pet, α^{EspC} enters epithelial cells where its serine protease subdomain (SD1) cleaves cell cytoskeleton-associated fodrin as well as cell attachment proteins paxillin and focal adhesion kinase, to cause cell rounding and detachment.^{22,23} However, EspC appears to have several defining attributes that set it apart from other autotransporters. The α^{EspC} can enter epithelium on its own, but its interaction with the type III secretion system accelerates and enhances its entry. As such, EspC remains the only autotransporter to utilize two major protein secretion systems, type III and V for bacterial secretion and cellular translocation.^{24,25} In addition to causing cell rounding, α^{EspC} can also induce cell death by activating the apoptosis and necrosis pathways.²⁶

In this study, we have elucidated the mechanisms by which the structural features of the EspC passenger domain (α^{EspC}) contribute to its role in

EPEC infections. Through determining the crystal structure of α^{EspC} and a detailed structure-function analysis, we have systematically dissected how specific structural elements of α^{EspC} enable its efficient entry into intestinal epithelial cells, leading to cytotoxic effects. This comprehensive approach offers new insights into the molecular interactions underlying EspC activity, which could pave the way for potential therapeutic interventions against EPEC-mediated diarrheal diseases.

Materials and methods

Bacterial strains, plasmids, and growth conditions

Bacterial strains and plasmid constructs used in this study are listed in Table S1. All strains were routinely grown aerobically in Luria-Bertani (LB) broth media or LB agar supplemented with 100 $\mu\text{g mL}^{-1}$ ampicillin.

Molecular cloning and construction of EspC mutants

Mutants of EspC were generated by mutagenesis using the Q5 Site-Directed Mutagenesis Kit (New England Biolabs, USA) with pBAD30:*espC* as the template.²³ The oligonucleotides used are listed in Table S2, and all constructs were confirmed by dideoxy nucleotide sequencing (Macrogen Inc., Korea).

Expression and purification of α^{EspC}

Plasmids encoding wildtype or mutant EspC were transformed into *E. coli* Top10 cells (Invitrogen), and cells grown aerobically in LB broth with 100 $\mu\text{g mL}^{-1}$ ampicillin to OD₆₀₀ of ~1. Protein expression was induced by adding 0.02% (w/v) L-arabinose for 24 h at 30°C for wildtype EspC or 20°C for EspC mutants. The culture supernatants containing secreted proteins (secreted passenger domains) were obtained by centrifugation at 8,000 $\times g$ for 30 min, filter sterilized (VacuCap 90 PF filter device; Pall Life Sciences, Australia), and concentrated 100-fold (Vivaflow 200, 30 kDa MWCO, Sartorius, Germany). The concentrated supernatants were dialyzed into 100 mM sodium acetate, pH 4–5, before cation exchange chromatography using HiTrap SP Fast Flow column (GE

Healthcare) with 50 mM sodium acetate (pH 4–5) and proteins eluted with a linear gradient to 500 mM NaCl. The pH of cation exchange buffers ranges from pH 4–5, depending on the isoelectric point of each α^{EspC} variant. Each protein was further purified by gel filtration chromatography using a Superdex 200 Increase 10/300 GL column (GE Healthcare) pre-equilibrated with phosphate-buffered saline (PBS). The purity of the fractions was analyzed by SDS-PAGE gels and Western blotting with α^{EspC} polyclonal antisera (1:25000). Protein concentrations were determined using a Nanodrop 2000 spectrophotometer (Thermo Fisher Scientific, USA), and proteins were flash-frozen in liquid nitrogen and stored at -80°C .

Crystallization and diffraction data measurement

Purified α^{EspC} (13 mg mL^{-1} in 25 mM HEPES, pH 7.0, 150 mM NaCl) was crystallized in 0.1 M Bis-Tris propane pH 7.4, 0.2 M potassium citrate and 15% (w/v) PEG 3350 using the hanging-drop vapor-diffusion technique. Harvested crystals (after 27 d incubation at 20°C) pre-equilibrated in reservoir solution containing 25% glycerol were flashed-cooled in liquid nitrogen.

Diffraction data for α^{EspC} were collected on the micro-crystallography beamline MX2 at the Australian Synchrotron. The reflection data were collected using an Eiger detector (Dectris, Baden-Dättwil, Switzerland) at a wavelength of 0.9537 \AA with a crystal-to-detector distance of 360 mm and a total angular rotation of 360° with an oscillation range of 0.1° per frame.

Structure determination of native α^{EspC}

Diffraction data were indexed, integrated and scaled with HKL2000 software,²⁷ and the α^{EspC} was solved by molecular replacement using Phaser²⁸ within the CCP4 suite²⁹ and the structure of EspP passenger domain (PDB:3SZE)³⁰ as a model. A model of α^{EspC} was completed by manually building Coot³¹ and refinement using Refmac5³² and Phenix refine³³ within the CCP4 suite. The structure quality was validated by the MolProbity³⁴ server and all the structural figures were generated by the molecular graphics tool PyMOL.³⁵ Details of data-processing

statistics and final refinement values are summarized in Table 1.

Protease activity assay

Protease activity was assessed using the EnzChek Protease Assay Kit (Invitrogen, E6638) as previously described.³⁶ Briefly, all reactions were carried out using 500 nM protein in a buffer

Table 1. α^{EspC} data collection and refinement statistics

Parameter	Native α^{EspC}
Data collection	
Detector	Eiger detector (Dectris, Baden-Dättwil, Switzerland)
Crystal to detector distance (mm)	360
Temperature (K)	100
Wavelength (\AA)	0.9537
Total/processed frames	3600
Oscillation ($^{\circ}$)	0.1
Exposure time per frame (s)	0.2
Space group	C121
Cell dimensions a, b, c (\AA)	213.469, 94.348, 139.831
α, β, γ ($^{\circ}$)	90, 108.163, 90.00
Resolution (\AA)	50.00–3.06 (6.35–2.95)
Rpim (%)	7.4 (40.4)
Rmeas (%)	18.0 (92.7)
CC _{1/2} (%)	99.0 (74.6)
I/ σ (I)	9.3 (1.3)
Completeness (%)	99.1 (96.2)
Redundancy	5.8 (4.7)
Refinement	
Resolution (\AA)	48.20–2.94 (3.04–2.95)
Completeness (%)	97.42%
Number of reflections	55249 (1864)
Rwork/Rfree	16.28/22.28
Number of non-H atoms	14482
Protein	14167
Ligand	159
Solvent	156
Average B-factor	65.24
Macromolecules	65.25
Solvent	53.20
R.m.s. deviations	
Bond length (\AA)	0.007
Bond angle ($^{\circ}$)	0.92
Ramachandran plot	
Most favoured (%)	93.95
Allowed (%)	5.83
Outliers (%)	0.22

Statistics for the highest-resolution shell are shown in parentheses.

$R_{\text{merge}} = \sum |I - \langle I \rangle| / \sum \langle I \rangle$ where I is the intensity of individual reflections.
 $R_{\text{fac}} = \sum_h |F_o - F_c| / \sum_h |F_o|$, where F_o and F_c are the observed and calculated structure-factor amplitudes for each reflection “h”.

R_{free} was calculated with 5% of the diffraction data selected randomly and excluded from refinement.

containing 50 mM Tris, 150 mM NaCl, and 0.005% Triton X-100 at pH 7.4. Fluorescence measurements were recorded at excitation/emission wavelengths of 485/520 nm using a FLUOstar Omega plate reader (BMG Labtech).

Circular dichroism spectroscopy

Circular dichroism (CD) spectroscopy was carried out using an Aviv 420 CD spectrophotometer (USA). Wavelength scans were performed between 195 and 250 nm in a quartz cuvette with a 1.0 mm pathlength and a protein concentration of 0.2 mg · mL⁻¹ in PBS. The data were collected at 20°C with 0.5 nm increments and 5 s averaging time. The protein signal was normalized against the buffer signal and converted into molar ellipticity using the equation below.

Conversion of CD millidegrees into mean residue ellipticity (MRE [θ]):

$$[\theta] = \text{CD}(\text{millidegrees}) * \frac{1}{\text{MRC} * \text{pathlength}(\text{mm})}$$

Calculation of mean residue concentration (MRC):

$$\text{MRC} = \frac{\text{amino acid count}}{\text{MW}(\frac{\text{g}}{\text{mol}})} * \text{concentration}(\frac{\text{mg}}{\text{ml}})$$

Where [θ] is the mean residue ellipticity value (°cm² dmol⁻¹).³⁷

Thermal melts

Thermal unfolding of α^{EspC} was determined as previously described.³⁶ Briefly, measurements were carried out using an Aviv 420 circular dichroism (CD) spectrophotometer (USA) which monitored the CD signal at 222 nm while increasing the temperature from 20°C to 90°C at a rate of 0.5°C/min. Experiments were conducted using 1 mm pathlength quartz cuvettes (Hellma) containing 200 μ L of protein at a concentration of 0–0.2 mg · mL⁻¹ in PBS. The apparent melting temperature (T_m^{app}) was determined by fitting the data to the following equation:

$$y = \frac{k}{1 + k} [(u + u_1x) - (l + l_1x)] + l + l_1x$$

Where, y represents absorbance, $k = e^{\left[\frac{h}{1.987(x+273.15)}\right] \left[\frac{x+273.15}{t+273.15} - 1\right]}$, x is temperature, h denotes enthalpy, t is T_m^{app} , u and l correspond to the folded and unfolded absorbance values, respectively, and u_1 and l_1 account for the linear temperature dependence of folded and unfolded states

Cell culture

HEp-2 cells were maintained in Dulbecco's Eagle's medium (DMEM) (Gibco) supplemented with 10% fetal bovine serum (FBS) (Corning) and 2 mM L-glutamine (Gibco) to support optimal growth. Cultures were incubated at 37°C in a humidified atmosphere containing 5% CO₂ to mimic physiological conditions. Upon reaching approximately 80–90% confluence, cells were dissociated using trypsin-EDTA (Gibco) to detach them from the culture surface. Detached cells were centrifuged, resuspended in fresh complete DMEM, and seeded into new culture vessels at appropriate dilutions for propagation.

Fluorescence microscopy

Activation of the T3SS²³ in REPEC (rabbit enteropathogenic *E. coli*) was done by diluting overnight REPEC cultures (1:50) into CD-CHO media (Gibco) with no supplements, followed by overnight incubation at 37°C in 5% CO₂. To prepare HEp-2 cells for infection, cells were seeded onto sterile 18 mm glass coverslips (Marienfeld 0,117,580) using 12-well tissue culture plates (Greiner 665,180). Each well received 1.3×10^5 cells suspended in DMEM supplemented with 10% fetal bovine serum (FBS) and 2 mM L-glutamine (L-Gln). The cells were incubated for 48 h at 37°C in a 5% CO₂ atmosphere, allowing for adequate adherence and growth. Post-incubation, the cells were washed with PBS, and the medium was replaced with CD-CHO (Gibco) to align with bacterial culture conditions.

HEp-2 cells were then exposed to 100 μ L of REPEC cultures adjusted to an optical density (OD₆₀₀) of approximately 0.6. Simultaneously, purified α^{EspC} proteins – either wildtype or mutant variants – were added to each well at a concentration of 60 μ g. Following a 6 h infection

period, cells were treated with gentamicin at a final concentration of 100 µg/mL for 1 h to eliminate extracellular bacteria. The cells were then washed thoroughly with PBS to remove any residual gentamicin and bacteria.

For microscopic analysis, cells were fixed with 4% formalin in PBS for 10 min in the absence of light, followed by washing in PBS containing 100 mM glycine. After permeabilisation with 0.2% Triton X-100 in PBS for 5 min, cells were blocked using 2% BSA dissolved in PBS containing 0.05% Tween-20 (PBS-T) for 1 h at room temperature or overnight at 4°C. The fixed and blocked cells were incubated for 2 h with rabbit polyclonal antisera specific to α^{EspC} (1:100 dilution), generated against the purified passenger domain at the Walter and Eliza Hall Antibody Facility (Australia). Secondary labeling involved Alexa Fluor Plus 647-conjugated goat anti-rabbit antibody (1:200, Invitrogen, A32733), applied for 1 h. To visualize actin structures, cells were stained with Phalloidin-iFluor 555 reagent (1:1000, Abcam, ab176756) for 30 min. Nuclei were counterstained with DAPI (1 µg/mL, Sigma, D9542) for 5 min in the dark.

Coverslips were mounted onto microscope slides using VECTASHIELD Antifade Mounting Medium (Vector Laboratories) to preserve fluorescence signals during imaging. Confocal microscopy was performed on a Zeiss LSM 780 microscope at magnifications of 10×, 40×, or 63×, depending on the required resolution. Images were processed in the FIJI³⁸ using the BIOP Channel Tools plugin.

Analytical ultracentrifugation

Sedimentation velocity analytical ultracentrifugation (SV-AUC) experiments were performed using a Beckman Optima XL-A analytical ultracentrifuge with an 8-hole An-50 Ti rotor. Double-sector quartz cells were loaded with 400 µL buffer (25 mM HEPES, pH 7.0 and 150 mM NaCl) and 480 µL α^{EspC} at 0.5, 1 and 2 mg mL⁻¹. The absorbance readings were collected at 280 nm and 40,000 rpm at 20°C in continuous mode. Solvent density, solvent viscosity and estimates of the partial specific volume of α^{EspC} at 20°C were calculated with SEDNTERP. Data were fitted with a continuous-size distribution model with SEDFIT.³⁹

Galleria mellonella toxicity assay

Toxicity assays were performed in *Galleria mellonella* as previously described.³⁶ Briefly, groups of seven larvae weighing approximately 180 mg each, were randomly selected and injected with 20 µL of purified α^{EspC} or $\alpha^{\text{EspC:PMSF}}$ with or without OD₆₀₀ ~0.05 EPEC diluted in sterile PBS. Injections were performed using a 1 mL U-100 insulin syringe (Terumo, 29 G × 13 mm) attached to a NE-1000 syringe pump (New Era). Following the injection, the larvae were transferred to a clean plate and incubated at 37°C. Mortality was assessed daily by gently prodding the larvae with tweezers. Larvae that exhibited no movement or response to physical stimuli were recorded as dead.

Results

Expression and purification of EspC passenger domain (α^{EspC})

Native full length *espC* from EPEC (0127:H6 E2348/69), cloned into pBAD30, was expressed in Top10 cells, which produced a 104 kDa secreted protein corresponding to the EspC functional passenger domain (α^{EspC} ; residues 54–1028). The culture supernatant, containing the untagged α^{EspC} , was collected and concentrated using tangential flow filtration followed by purification using cation exchange and size exclusion chromatography (Figure 1(a)). The purified α^{EspC} was shown to be proteolytically active using a fluorogenic casein-based substrate (Figure S1). Further, the protease activity of α^{EspC} strongly depended on the pH and salt concentration of the medium, where the highest activity was observed at pH 9.0 and 50 mM NaCl (Figure S1).

The overall architecture of the EspC passenger domain (α^{EspC})

The crystal structure of the passenger domain of EspC (α^{EspC}) was determined by molecular replacement to a resolution of 2.9 Å, using the passenger domain of EspP (PDB: 3SZE)³⁰ as a model and refined to a R_{free} of 22.28% (R_{work} 16.28%) (crystallographic statistics in Table 1). Crystals of α^{EspC} belonged to the C121 space group with two




Figure 1. Crystal structure of EspC passenger domain (α^{EspC}). (a) (left panel) linear schematic representation of EspC primary sequence, showing an N-terminal signal peptide (SP, residues 1–53), C-terminal translocator domain (residues 1029–1305) and central passenger domain (α^{EspC}) (residues 54–1028), which is the functional domain and mature toxin that is released into the extracellular environment. The conserved serine protease catalytic triad is highlighted in red and includes residues Ser256, His125 and Asp153. (right panel) SDS-PAGE analysis of purified α^{EspC} showing a band at ~100 kDa, consistent with the predicted molecular weight of 104 kDa. (b) Crystal structure of the EspC passenger domain (α^{EspC}) shown in cartoon representation, with the serine protease domain coloured in pale green (subdomain-1, SD1, residues 54–304) and the active site residues depicted as spheres. The right-handed β -helical stalk domain (residues 305–1028) is pink, with the C-terminal AC domain coloured in peach. The protruding α -helical subdomain-2 (SD2, residues 567–620) is coloured in yellow and the β -hairpin subdomain-3 (SD3, residues 666–696) in magenta. (c) Cartoon representation of the EspC SD1 protease domain that comprises a chymotrypsin-like fold containing the catalytic triad Ser256, His125 and Asp153 (yellow sticks). (d) 2Fo-fc electron density map coloured at 1σ encompassing the close-up view of the catalytic triad residues.

molecules in the asymmetric unit. However, as shown by sedimentation velocity analytical ultracentrifugation (AUC), α^{EspC} only identified as monomers in solution at concentrations up to 2 mg mL⁻¹ (Figure S2). Structural alignment of the two monomers in the asymmetric unit gave an overall r.m.s.d. value of 0.429 Å over all 949 Ca atoms, indicating their high structural similarity.

Each monomer of α^{EspC} contains 949 residues (numbered 54–1002) and is arranged into two

major domains, an N-terminal serine protease domain/subdomain-1 (SD1 residues 54–304; 251 aa) and a C-terminal β -helical stalk domain (β -helix residues 305–1002; 698 aa) (Figure 1(a, b)).

SD1 adopts a chymotrypsin-like fold comprised a tandem 6-stranded β -barrel architecture. The intervening surfaces of the two β -barrels harbor the protease active site residues His125, Asp153 and Ser256, with the barrels connected via an extended loop harboring a short α -helix (Figure 1(c,d)).

Additional features include an extended N-terminal loop with an α -helix and β -hairpin along with a third loop derived from the second β -barrel that forms a β -hairpin to pin the N-terminus.

The large right-handed β -helix subdomain includes the auto-chaperone (AC) domain at the C-terminus spanning from Thr919 to Thr1002 (84 aa), capped by a β -hairpin motif (Figure 1(b)). The β -helix stalk comprises 24 complete turns, with each turn containing about 20 residues forming 3 β -strands linked by loops. Like other ATs, the β -helix core is largely nonpolar, while polar residues decorate the exterior solvent-accessible surface. Extensions from the core β -helical domain form two additional domains, an α -helical subdomain-2 (SD2, residues 567–620) and a β -hairpin subdomain-3 (SD3, residues 666–694) (Figure 1(a, b)). SD2 consists of a 23-residue helix-turn-helix motif adjacent to SD1 domain, and a 20-residue loop comprising two Cys residues (Cys578 and Cys585) that form a disulfide bond. Mapping parallel to the β -helix stalk is SD3, forming a long β -hairpin loop consisting of 29 residues (Figure 1(b)).

Structural comparison using the Dali server⁴⁰ showed that α^{EspC} is most similar to class 1 SPATE passenger domains,⁵ including EspP from enterohaemorrhagic *E. coli* (41% sequence identity, PDB: 3SZE,³⁰ Z-score 42, r.m.s.d. 1.8 Å over 845 Ca atoms) and Pet from enteroaggregative *E. coli* (42% sequence identity, PDB: 4OM9,⁴¹ Z-score 39.4, r.m.s.d. 2.2 Å over 836 Ca atoms) (Figure S3). Like α^{EspC} , class 1 SPATEs contain protease and β -helix domains along with SD2 subdomain predominantly α -helical and positioned adjacent to the SD1 protease domain. In contrast, the equivalent subdomain in class 2 SPATEs, such as Hbp, adopts a chitinase-like structure, mapping in the opposite side of the β -helix relative to the protease domain, creating a distinctive Y-shaped structure.^{42,43} Additionally, class 1 SPATEs and α^{EspC} share a conserved GKNITGXGFXFRQ motif in the SD3 β -hairpin loop (Figure 3(b)), though its function is unknown.

EspC substrate binding pocket

Serine proteases feature a substrate binding site with multiple subsites (S1–S3 and S1–S3'), with the S1 pocket serving as the primary determinant

of substrate specificity.⁴⁴ To identify the putative binding pocket of α^{EspC} , and infer substrate specificities structural comparisons were made with structurally investigated serine proteases using DALI.⁴⁰ This analysis revealed that the closest ligand-bound serine protease to α^{EspC} is bovine pancreatic δ -chymotrypsin complexed with pancreatic trypsin inhibitor (BPTI) (PDB ID: 1CBW,⁴⁵ 16.7% sequence identity over 250 Ca atoms with r.m.s.d. of 2.0 Å). Structural superposition of the protease domains of α^{EspC} and δ -chymotrypsin-BPTI complex showed a perfect alignment of their catalytic triad residues (Figure 2(b)). This superposition also uncovered that the predicted α^{EspC} substrate binding pocket (residues 251–255, 277–281 and 287–291) is more open than that of δ -chymotrypsin, especially around the S1 subsite (Figure 2(d)). This feature is due to longer loops L1 (242–249) and L2 (282–287) near the α^{EspC} S1 binding pocket, along with the lack of a disulfide bond in this area, with a disulfide bond in chymotrypsin providing some restriction to this area (Figure 2(b)). EspC closest structural homologues Pet and EspP also have long L1 and L2 loops that lead to a large substrate binding pocket (Figure S3).

A comparison with the δ -chymotrypsin-BPTI complex revealed the complete α^{EspC} S3 to S3' subsite positions to be arranged as h-a-b//a-h-a (S3-S2-S1//S1'-S2'-S3'; a = acidic, b = basic, h = hydrophobic). These subsites differ from the mostly acidic subsites in chymotrypsin, which are h-a-a//a-a-a (Figure 2(c)), particularly the primary S1 subsite, which in EspC harbors a positively charged Arg 200 residue.

Further comparison of the substrate binding sites of EspC with those of Pet, also determined based on its structural superposition with the δ -chymotrypsin-BPTI complex, showed notable differences between these two class 1 SPATEs. The α^{Pet} S3 to S3' subsites were predicted to be h-a-h/a//b-b-b for S3-S2-S1//S1'-S2'-S3', respectively, highlighting several difference including the main S1 subsite which is mostly hydrophobic in Pet and basic EspC (Figure S4).

Extracellular secretion of α^{EspC} is independent of SD1, SD2 and SD3

Recently, it has been shown that the SD2 of α^{Pet} plays a prominent role in host cell binding as the




Figure 2. Comparison of the α^{EspC} protease domain and bovine chymotrypsin. (a) The protease domain of α^{EspC} in cartoon representation shows the catalytic triad (Ser256, His125 and Asp153) as green sticks and the S1 binding pockets in blue. The binding pocket extension loops of L1 and L2 are coloured in red, and the S1 subsite Arg200 is highlighted as yellow sticks. (b) Superimposition of the crystal structure of the protease domain of α^{EspC} (pale green) and bovine chymotrypsin in grey (PDB:1CBW). Close-up view of superimposed molecules showing the alignment of the catalytic triad of δ -chymotrypsin (Ser195, His57 and Asp102) and α^{EspC} (Ser256, His125 and Asp153). The substrate binding pocket S1 of α^{EspC} and bovine chymotrypsin are shown in blue and cyan colours, respectively. The S1 subsite of α^{EspC} (arg 200) is shown as a yellow stick. L1 and L2 loops of α^{EspC} and bovine chymotrypsin are shown in red and pink, respectively. Two cyste residues of bovine chymotrypsin (C191 and C220) are shown in cyan sticks with sulphur atoms in orange. Catalytic triad residues of α^{EspC} in green (labelled) and bovine chymotrypsin in grey are shown as sticks. (c) Electrostatic surface of bovine chymotrypsin in complex with the basic pancreatic trypsin inhibitor (BPTI). The principal binding site residues (Pro13 to Ile18) of BPTI are shown as yellow sticks. Close up of subsites are labelled in insets. (d) The electrostatic surface of α^{EspC} protease domain. Putative protease subsites are indicated in the inset. The electrostatic surface potentials were calculated with the APBS plugin in Pymol with electrostatic potential coloured from negative (red) to positive (blue) with a range of ± 5 kT/e.




Figure 3. α^{EspC} variants and their protease activity (a) top diagram shows the linear schematic representation of wild type α^{EspC} , highlighting SD1 (residues 55–310), SD2 (residues 575–627) and SD3 (residues 671–696). Additionally, we show α^{EspC} variants with deletions to these domains; $\alpha^{EspC\Delta SD1}$, $\alpha^{EspC\Delta SD2}$, $\alpha^{EspC\Delta SD3}$ along with $\alpha^{EspC\Delta SD3\Delta loop}$ lacking a SD3 loop (GKNITGDGFGFRQ). (b) Cartoon representation of α^{EspC} showing SD1 (green), SD2 (yellow) and SD3 (magenta). Inset 1 shows a detailed view of the SD1-SD2 interface highlighting the residues mutated in the $\alpha^{EspC-SD1/SD2}$ mutant (H568A, K587A, Q596A, E597A and N601A). Inset 2 displays the sequence alignment of class 1 SPATEs α^{EspC} , α^{EspP} and α^{Pet} loop regions, depicting the residues modified in the $\alpha^{EspC-SD3\Delta loop}$ mutant. (c) SDS-page analysis of active wild-type α^{EspC} and its inactivated PMSF-treated variant, as well as α^{EspC} mutants $\alpha^{EspC\Delta SD1}$, $\alpha^{EspC\Delta SD2}$, $\alpha^{EspC\Delta SD3}$, $\alpha^{EspC\Delta SD3\Delta loop}$ and $\alpha^{EspC\Delta SD3\Delta loop}$. (d) Protease activity of α^{EspC} and its mutants determined by the digestion of a fluorogenic casein substrate at 37°C. The means are shown with error bars representing the standard deviation from three replicates.

deletion of SD2 prevents Pet binding to the cell surface receptor cytochrome-8 (CK-8).¹⁴ To determine the region(s) of α^{EspC} that facilitate internalization of α^{EspC} in the presence of T3SS, we initially generated three deletion mutants by deleting SD1 (residues 54–304), SD2 (residues 567–620) and SD3 (residues 666–694), referred to as $\alpha^{EspC\Delta SD1}$, $\alpha^{EspC\Delta SD2}$ and $\alpha^{EspC\Delta SD3}$, respectively (Figure 3(a, b)). We successfully overexpressed and purified these deletion mutants from the culture supernatant (Figure 3(c)), confirming that SD1, SD2 and SD3 are not required for secretion of α^{EspC} . The correct structure of these deletion mutant proteins was supported by all of them showing a close wavelength profile (198–250 nm) and melting

temperature (60–68°C) to that of wildtype α^{EspC} by circular dichroism spectroscopy (Figure S5–6).

α^{EspC} proteolytic activity depends on subdomain-2 (SD2)

To assess the role of α^{EspC} structural subdomains in its protease activity, we compared the enzymatic activity of all α^{EspC} variants against a casein-based substrate. Deletion of the protease domain (SD1), as expected, completely abolished protease activity. Remarkably, deletion of SD2 also resulted in a dramatic reduction the protease activity of α^{EspC} compared to wild type α^{EspC} (Figure 3(d)). This was surprising given that the protease activity was




Figure 4. T3SS mediated α^{EspC} internalisation is independent of its major subdomains, including SD1, SD2 and SD3. HEp-2 cells were infected with REPEC and co-incubated with 60 μg of α^{EspC} variants for 6 h, followed by 1 h gentamicin treatment. The α^{EspC} was visualised with anti- α^{EspC} polyclonal antibody followed by Alexa Fluor Plus 647 conjugated secondary antibody (yellow). Actin cytoskeletal and nucleus were stained with Phalloidin (magenta) and DAPI (cyan), respectively. α^{EspC} variants include wild type (α^{EspC}), deletion of SD1 ($\alpha^{\text{EspC}\Delta\text{SD1}}$), SD2 ($\alpha^{\text{EspC}\Delta\text{SD2}}$), SD3 ($\alpha^{\text{EspC}\Delta\text{SD3}}$) and a deletion of the SD3 loop motif ($\alpha^{\text{EspC-SD3}\Delta\text{loop}}$). PMSF inactivated variants were denoted by +PMSF. Images are representative of cells observed from at least three independent experiments. The scale bar represents 100 μm (lower right).

thought to solely depend on the SD1 domain.¹⁴ SDS-PAGE analysis (Figure 3(c)) showed that the Δ SD2 variant consists of two major protein species (~100 kDa and ~75 kDa), with the full-length protein representing approximately 47% of the total sample based on densitometry. If only the full-length Δ SD2 variant retained activity and assuming its enzymatic function was unaffected by SD2 deletion, we would expect at least 40% of wild-type activity. However, the observed activity was less than 5%, indicating that SD2 plays a role possibly stabilizing the protease domain for efficient catalysis.

Analysis of all available SPATE structures showed that the SD2 is situated adjacent to the SD1 and connected via a network of inter-domain hydrogen bonds and salt bridges formed (H568 – D68, K587 – S216, Q596 – T208 and Q210, E597 – A63 and K88, in α^{EspC}). To explore the role of these interactions, we generated the interface mutant $\alpha^{\text{EspC-SD1/SD2}}$ by substituting these residues with alanine. Unfortunately, although this mutant was secreted, it was unstable, preventing further examination. Our data, however, indicate that SD1 protease activity seems to rely on SD2, likely due to its stabilizing role, which helps maintain the protease activity of the SD1 domain.

SD1, SD2 or SD3 are not required for α^{EspC} T3SS mediated host cell internalization

To dissect the mechanism of α^{EspC} host cell internalization, HEp-2 monolayers were incubated with purified EspC passenger domain including α^{EspC} deletion mutants ($\alpha^{\text{EspC}\Delta\text{SD1}}$, $\alpha^{\text{EspC}\Delta\text{SD2}}$ and $\alpha^{\text{EspC}\Delta\text{SD3}}$) along with native α^{EspC} and PMSF inactivated α^{EspC} (Figure 4). All EspC internalization assays were conducted in the presence of rabbit enteropathogenic *E. coli* (REPEC), which does not harbor the *espC* gene but does express a T3SS, which is required for efficient T3SS-mediated EspC internalization.²³ Interestingly, all subdomain deletion mutants of α^{EspC} , including $\alpha^{\text{EspC}\Delta\text{SD1}}$, $\alpha^{\text{EspC}\Delta\text{SD2}}$ and $\alpha^{\text{EspC}\Delta\text{SD3}}$, were able to enter HEp-2 cells similar to wild type α^{EspC} (Figure 4), revealing that none of these major subdomains are required for its T3SS mediated cell entry.

A detailed examination of the HEp-2 internalization assays showed that the $\alpha^{\text{EspC}\Delta\text{SD3}}$ variant exhibited higher internalization rates and caused more extensive cell damage compared to wild-type α^{EspC} , as seen by increased levels of cell rounding and detachment compared to wild type α^{EspC} (Figure 4). The cell damage was attributed to the SPATE's serine protease domain (SD1), as PMSF inactivated $\alpha^{\text{EspC}\Delta\text{SD3}}$ (Figure 4) completely abolished the cytotoxicity. However, given that $\alpha^{\text{EspC}\Delta\text{SD3}}$ did not show increased protease activity compared to the wildtype (Figure 3(d)), the increased cytotoxicity was due to higher levels of $\alpha^{\text{EspC}\Delta\text{SD3}}$ penetrating into the HEp-2 cells. The conserved GKNITGXGFXFRQ motif in SD3 across class 1 SPATEs (Figure 3(b)) suggests that this subdomain plays a crucial role (Figure 3(b)). However, internalization assays with $\alpha^{\text{EspC-SD3}\Delta\text{loop}}$ mutant that contains this motif did not significantly alter internalization levels (Figure 4).

Together, these findings indicate that EspC internalization, mediated by the T3SS, does not rely on the protease activity of SD1 or the protruding SD2 and SD3, pointing to an active role of the core β -helix in facilitating cell entry.⁴⁶ Furthermore, the removal of SD3, which maps parallel to the middle section of the β -helix (Figure S8), enhanced internalization, possibly indicating that this modification improves the β -helix's ability to interact with the T3SS for more efficient internalization.⁴⁶

α^{EspC} shows higher toxicity in vivo in the presence of T3SS

Given that α^{EspC} induces cytopathic effects on human epithelial cells, we investigated its effects *in vivo* in a *Galleria mellonella* larva model, which has been used to study the cytotoxicity of the subtilase autotransporter Ssp.³⁶ Purified α^{EspC} of varying concentrations was administered by intrahemocoel injection, either in the presence or absence of EPEC which contains the T3SS, and larvae mortality was monitored. In the absence of EPEC (T3SS), dosing of 500 mg kg⁻¹ EspC (body weight) was required to cause 100% mortality, compared to PMSF-inactivated EspC, which caused no mortality at similar concentrations (Table 2). However, in the presence of 0.05 OD₆₀₀ EPEC (T3SS), dosing of 250 mg kg⁻¹ EspC showed 100% larva mortality, increasing the toxicity of

Table 2. Percentage of surviving *G. mellonella* larvae after 24 h, post-injection with purified α^{EspC} and $\alpha^{\text{EspC:PMSF}}$ in the presence or absence of 0.05 OD₆₀₀ EPEC (T3SS).

Dose (mg kg ⁻¹)	α^{EspC}	$\alpha^{\text{EspC:PMSF}}$
Absence of 0.05 OD ₆₀₀ EPEC (T3SS)		
650	0%	100%
500	0%	100%
400	100%	100%
200	100%	100%
100	100%	100%
50	100%	100%
Presence of 0.05 OD ₆₀₀ EPEC (T3SS)		
400	0%	100%
250	0%	100%
0	100%	100%

EspC by two-fold (Table 2). No mortality was observed when larvae were treated with equivalent amount of EPEC (T3SS) alone. Collectively, these results highlight the importance of the α^{EspC} serine protease in causing cellular toxicity and the role of the T3SS in efficiently delivering α^{EspC} to host tissue.

Discussion

EPEC is a serious diarrheal pathogen, particularly in infants, which produces attaching and effacing lesions in the intestinal epithelium.^{17,47,48} Here, we reveal the crystal structure of the autotransporter EspC, the first protein secreted during EPEC infection of epithelial cells,⁴⁹ and a major enterotoxin that plays a central role in cytotoxicity, primarily via its serine protease activity.^{23,50} Upon internalization, EspC induces the degradation of key cellular components such as fodrin and focal adhesion proteins, leading to cell rounding, detachment, and eventual cell death.^{23,51,52} Although EspC uses the autotransporter system for transport to the bacterial surface, it takes advantage of the type III secretion system for injection into the intestinal epithelium.^{23,53} Guided by our crystal structure, we dissect the role of the EspC subdomains required for internalization and cell rounding of the intestinal epithelium.

Our structure of the EspC passenger domain (α^{EspC}) showed strong structural conservation to other SPATEs, particularly the Class 1 SPATEs,⁴² despite the modest sequence identity (~40%). Key structural features include the long β -helix, N-terminal serine protease domain SD1, as well as the α -helical SD2 and β -hairpin SD3 domains. Given

the unique ability of α^{EspC} to utilize the type III system for cell entry, it is notable that this function is linked with to the conserved core β -helix structure, conserved among autotransporters, and not to the distinctive protruding loops and domains.

The EspC protease SD1 is essential for its cytotoxicity toward epithelial cells. This aligns with previous findings on EspC and related SPATEs such as Pet, where the serine protease degrades intracellular proteins like fodrin, paxillin and focal adhesion kinase to cause cell rounding and detachment.^{22,23} However, as also shown for Pet,¹⁴ the serine protease activity of EspC is not required for cell entry, which contrasts with other autotransporters such as Ssp, where the protease activity is required for both cell entry and toxicity.³⁶

Structurally, the α^{EspC} protease domain adopts a chymotrypsin-like fold similar to other SPATEs, but with an expanded substrate binding S1 pocket due to longer L1 and L2 loops and the absence of a tethering disulfide bond in this region. This open binding site, also conserved in EspC's closest homologues EspP and Pet, may facilitate these proteases to cleave large oligomeric substrates, including fodrin, paxillin, and focal adhesion kinase.²⁵

Mapping the putative protease binding subsites of EspC, in comparison to the δ -chymotrypsin-BPTI complex, revealed a basic electrostatic region near the S1 subsite, facilitated by Arg200. In proteases like chymotrypsin, the S1 subsite plays a pivotal role in determining substrate specificity, and EspC appears to follow a similar principle. EspC cleaves the protein fodrin at specific sites, such as LCQ/LAE and MSD/LSA,²³ suggesting that its S1 subsite is adapted to recognize acidic or polar residues in its substrate. In contrast, while the SPATE Pet also cleaves fodrin, previous studies have demonstrated that it targets a distinct cleavage site, specifically between Met1198 and Val1199.⁵⁴ This difference aligns with the distinct surface charge properties of Pet where the S1 subsite, is more hydrophobic and thus better suited to interact with hydrophobic residues like methionine.

Although SD2 and SD3 do not appear directly involved in EspC's entry or cytotoxicity, they seem to play supporting roles. Removal of SD2 reduced the protease activity of EspC, suggesting that SD2 may stabilize or orient SD1 for optimal function.

This partnership is possibly only required in the context of the full-length passenger domain, as isolated SPATE protease SD1, including from EspC, has been reported to retain significant protease activity.^{14,46,55} Nevertheless, the residual activity of α^{EspC} after removing the SD2 was still sufficient to generate substantial rounding of epithelial cells. SD2 function in EspC differs from the equivalent subdomain in the related Pet, which was shown to be required for cell entry.¹⁴ This distinction is likely due to their different cell entry mechanisms, with Pet using receptor-mediated endocytosis⁵⁶ and EspC the type III.^{24,25}

Although not critical for cell entry or toxicity, deletion of the β -hairpin SD3 appeared to increase both cell entry and cytotoxicity of α^{EspC} into epithelial cells. This enhanced cytotoxicity was attributed to the serine protease activity, as shown by the complete loss of toxicity in the PMSF-inactivated SD3 deletion mutant. However, since the SD3 deletion mutant retains only 40% of the protease activity of full-length EspC *in vitro*, the observed effects may reflect a combination of increased cell entry rates and the mutant's inherent baseline activity. As we and others show, this cell entry depends largely on the type III secretion system.⁵³ The interaction site for the type III system on α^{EspC} was previously mapped to residues 429–449,⁴⁶ a region analogous to the translocator motif of YopH in *Yersinia*, which also depends on the T3SS for internalization.⁵⁷ We have now identified this motif within the EspC structure, spanning six to seven β -strand rungs of the β -helix domain. The β -helix, a well-known feature of autotransporters, plays a key role in mediating protein interactions, similar to how autotransporter adhesins interact with host proteins or polysaccharides.^{58,59} Further analysis of the crystal structure reveals that the SD3 β -hairpin partially covers the type III interaction site, suggesting that SD3 regulates EspC's interaction with the type III secretion system. Its removal seems to expose this interaction site, facilitating increased cell entry. This is the first time the role of a SPATE SD3 has been characterized. While SD3-like subdomains are common across SPATEs, they have no recorded involvement with type III systems, indicating that SD3 might serve a different, yet unidentified, role in other SPATEs.

In conclusion, our study provides important insights into the structure–function relationships of the autotransporter α^{EspC} , which utilizes a type III secretion system to enter epithelial cells. We have identified distinct roles for EspC's structural domains in mediating cell entry and cytotoxicity. Specifically, the SD1 and SD2 domains are critical for protease activity and the associated cytotoxic effects. In contrast, in its closest homologue Pet, these domains play different roles, regulating toxicity and cell entry, respectively.¹⁴

Although the function of the SD3 domain in autotransporters remains unclear, our findings suggest that while SD3 is not directly required for EspC internalization, it may play a regulatory role in modulating cell entry. Notably, the removal of SD3 enhances internalization, suggesting that the central region of the β -helix, partially covered by SD3, is crucial for cell entry. Its absence appears to increase both internalization and cytotoxicity, highlighting the complex interplay between structural elements and functional outcomes.

Collectively, our findings highlight the specialized features of cell-penetrating autotransporters, and provide insights into their diverse mechanisms for facilitating host cell entry and cytotoxicity.

Acknowledgments

This research was undertaken in part using the MX2 beamline at the Australian Synchrotron, part of ANSTO, and made use of the Australian Cancer Research Foundation (ACRF) detector. The authors would like to acknowledge the La Trobe University Bioimaging Platform. We also thank Prof. Jaclyn Pearson (Hudson Institute of Medical Research), for kindly providing the EPEC, Dr Dianna Hocking (University of Melbourne) for providing the REPEC.








Disclosure statement

No potential conflict of interest was reported by the author(s).

Funding

This work was supported by the Australian Research Council (ARC) project grant [DP210100673], a National Health and Medical Research Council (NHMRC) project grant [GNT1143638] and an ARC Future Fellowship [FT150100452].

ORCID

Akila U. Pilapitiya  <http://orcid.org/0000-0001-9821-467X>
 Lilian Hor  <http://orcid.org/0000-0002-2967-0134>
 Lakshmi C. Wijeyewickrema  <http://orcid.org/0000-0001-6084-4887>
 Robert N. Pike  <http://orcid.org/0000-0002-2083-0269>
 Denisse L. Leyton  <http://orcid.org/0000-0003-4808-9289>
 Jason J Paxman  <http://orcid.org/0000-0002-1418-5910>
 Begoña Heras  <http://orcid.org/0000-0003-3469-7988>

Data availability statement

The authors confirm that data supporting the findings of this study are available within the article or upon request from the corresponding author.

Data deposition

The crystallography, atomic coordinates, and structure factors reported in this paper have been deposited in the Protein Data Bank under PDB ID 9MNE. The following structural models from the PDB were also used in this study: 3SZE (EspP from enterohaemorrhagic *E. coli*), 4OM9 (Pet from enteroaggregative *E. coli*), 1CBW (bovine pancreatic δ -chymotrypsin with pancreatic trypsin inhibitor).

References

- James BK, James PN, Harry LTM. Pathogenic *Escherichia coli*. *Nat Rev Microbiol*. 2004;2(2):123. doi: 10.1038/nrmicro818.
- Black RE, Cousens S, Johnson HL, Lawn JE, Rudan I, Bassani DG, Jha P, Campbell H, Walker CF, Cibulskis R, et al. Global, regional, and national causes of child mortality in 2008: a systematic analysis. *Lancet*. 2010;375(9730):1969–1987. doi: 10.1016/S0140-6736(10)60549-1.
- WHO. Antimicrobial resistance: global report on surveillance. 2014;257. <http://www.who.int/drugresistance/documents/surveillance-report/en/>.
- Leyton DL, Sevastyanovich YR, Browning DF, Rossiter AE, Wells TJ, Fitzpatrick RE, Overduin M, Cunningham AF, Henderson IR. Size and conformation limits to secretion of disulfide-bonded loops in autotransporter proteins. *J Biol Chem*. 2011;286(49):42283–42291. doi: 10.1074/jbc.M111.306118.
- Ruiz-Perez F, Nataro JP. Bacterial serine proteases secreted by the autotransporter pathway: classification, specificity, and role in virulence. *Cell Mol Life Sci*. 2014;71(5):745–770. doi: 10.1007/s00018-013-1355-8.
- Dautin N. Serine protease autotransporters of enterobacteriaceae (SPATEs): biogenesis and function. *Toxins*. 2010;2(6):1179–1206. doi: 10.3390/toxins2061179.
- Vo JL, Martínez Ortiz GC, Subedi P, Keerthikumar S, Mathivanan S, Paxman JJ, Heras B. Front cover: autotransporter adhesins in *Escherichia coli* pathogenesis. *Proteomics*. 2017;17(23–24). doi: 10.1002/pmic.2017700181.
- Celik N, Webb CT, Leyton DL, Holt KE, Heinz E, Gorrell R, Kwok T, Naderer T, Strugnell RA, Speed TP, et al. A bioinformatic strategy for the detection, classification and analysis of bacterial autotransporters. *PLOS ONE*. 2012;7(8):e43245. doi: 10.1371/journal.pone.0043245.
- Henderson IR, Navarro-Garcia F, Desvaux M, Fernandez RC, Ala'aldien D. Type V protein secretion pathway: the autotransporter story. *Microbiol Mol Biol Rev*. 2004;68(4):692–744. doi: 10.1128/mmbr.68.4.692-744.2004.
- Jose J, Jahnig F, Meyer TF. Common structural features of IgA1 protease-like outer membrane protein autotransporters. *Mol Microbiol*. 1995;18(2):378–380. doi: 10.1111/j.1365-2958.1995.mmi_18020378.x.
- Henderson IR, Navarro-Garcia F, Nataro JP. The great escape: structure and function of the autotransporter proteins. *Trends Microbiol*. 1998;6(9):370–378. doi: 10.1016/S0966-842X(98)01318-3.
- Leyton DL, Belousoff MJ, Lithgow T. The β -barrel assembly machinery complex. *Methods Mol Biol*. 2015;1329:1–16. doi: 10.1007/978-1-4939-2871-2_1.
- Eslava C, Navarro-García F, Czczulin JR, Henderson IR, Cravioto A, Nataro JP. Pet, an autotransporter enterotoxin from enteroaggregative *Escherichia coli*. *Infect Immun*. 1998;66:3155–3163.
- Chavez-Duenas L, Serapio-Palacios A, Nava-Acosta R, Navarro-Garcia F. Subdomain 2 of the Autotransporter Pet is the ligand site for recognizing the pet receptor on the epithelial cell surface. *Infect Immun*. 2016;84:2012–2021. doi: 10.1128/IAI.01528-15.
- Nava-Acosta R, Navarro-Garcia F. Cytokeratin 8 is an epithelial cell receptor for pet, a cytotoxic serine protease autotransporter of enterobacteriaceae. *mBio*. 2013;4:e00838–00813. doi: 10.1128/mBio.00838-13.
- Villaseca JM, Navarro-García F, Mendoza-Hernández G, Nataro JP, Cravioto A, Eslava C. Pet toxin from enteroaggregative *Escherichia coli* produces cellular damage associated with fodrin disruption. *Infect Immun*. 2000;68(10):5920–5927. doi: 10.1128/IAI.68.10.5920-5927.2000.
- Mare AD, Ciurea CN, Man A, Tudor B, Moldovan V, Decean L, Toma F. Enteropathogenic *Escherichia coli*—A summary of the literature. *Gastroenterol Insights*. 2021;12(1):28–40. doi: 10.3390/GASTROENT12010004.
- Mellies JL, Navarro-Garcia F, Okeke I, Frederickson J, Nataro JP, Kaper JB. espC pathogenicity island of enteropathogenic *Escherichia coli* encodes an enterotoxin. *Infect Immun*. 2001;69(1):315–324. doi: 10.1128/iai.69.1.315-324.2001.

19. Jarvis KG, Giron JA, Jerse AE, McDaniel TK, Donnenberg MS, Kaper JB. Enteropathogenic *Escherichia coli* contains a putative type III secretion system necessary for the export of proteins involved in attaching and effacing lesion formation. *Proceedings of the National Academy of Sciences - PNAS*. 1995;92:7996–8000. doi: [10.1073/pnas.92.17.7996](https://doi.org/10.1073/pnas.92.17.7996).
20. Cornelis GR. The type III secretion injectisome. *Nat Rev Microbiol*. 2006;4(11):811–825. doi: [10.1038/nrmiicro1526](https://doi.org/10.1038/nrmiicro1526).
21. Galan JE, Wolf-Watz H. Protein delivery into eukaryotic cells by type III secretion machines. *Nature*. 2006;444(7119):567–573. doi: [10.1038/nature05272](https://doi.org/10.1038/nature05272).
22. Navarro-Garcia F, Serapio-Palacios A, Vidal JE, Isabel Salazar M, Tapia-Pastrana G, McCormick BA. EspC promotes epithelial cell detachment by enteropathogenic *Escherichia coli* via sequential cleavages of a cytoskeletal protein and then focal adhesion proteins. *Infect Immun*. 2014;82(6):2255–2265. doi: [10.1128/IAI.01386-13](https://doi.org/10.1128/IAI.01386-13).
23. Navarro-García F, Canizalez-Roman A, Sui BQ, Nataro JP, Azamar Y. The serine protease motif of EspC from enteropathogenic *Escherichia coli* produces epithelial damage by a mechanism different from that of pet toxin from enteroaggregative *E. coli*. *Infect Immun*. 2004;72(6):3609–3621. doi: [10.1128/iai.72.6.3609-3621.2004](https://doi.org/10.1128/iai.72.6.3609-3621.2004).
24. Vidal JE, Navarro-Garcia F. EspC translocation into epithelial cells by enteropathogenic *Escherichia coli* requires a concerted participation of type V and III secretion systems. *Cellular Microbiol*. 2008;10(10):1975–1986. doi: [10.1111/j.1462-5822.2008.01181.x](https://doi.org/10.1111/j.1462-5822.2008.01181.x). (2008).
25. Navarro-Garcia F, Sonnested M, Teter K. Host-toxin interactions involving EspC and pet, two serine protease autotransporters of the Enterobacteriaceae. *Toxins (Basel)*. 2010;2:1134–1147. doi: [10.3390/toxins2051134](https://doi.org/10.3390/toxins2051134).
26. Serapio-Palacios A, Navarro-Garcia F. EspC, an auto-transporter protein secreted by enteropathogenic *Escherichia coli*, causes apoptosis and necrosis through caspase and calpain activation, including direct procaspase-3 cleavage. *Microbiology*. 2016;7:e00479–00416. doi: [10.1128/mBio.00479-16](https://doi.org/10.1128/mBio.00479-16).
27. Otwinowski Z, Minor W. Processing of X-ray diffraction data collected in oscillation mode. *Methods Enzymol*. 1997;276:307.
28. McCoy AJ, Grosse-Kunstleve RW, Adams PD, Winn MD, Storoni LC, Read RJ. Phaser crystallographic software. *J Appl Crystallogr*. 2007;40(4):658–674. doi: [10.1107/S0021889807021206](https://doi.org/10.1107/S0021889807021206).
29. Winn MD, Ballard CC, Cowtan KD, Dodson EJ, Emsley P, Evans PR, Keegan RM, Krissinel EB, Leslie AGW, McCoy A, et al. Overview of the CCP4 suite and current developments. *Acta Crystallogr D Biol Crystallogr*. 2011;67(4):235–242. doi: [10.1107/S0907444910045749](https://doi.org/10.1107/S0907444910045749).
30. Khan S, Mian HS, Sandercock LE, Chirgadze NY, Pai EF. Crystal structure of the passenger domain of the *Escherichia coli* autotransporter EspP. *J Mol Biol*. 2013;413. doi: [10.1016/j.jmb.2011.09.028](https://doi.org/10.1016/j.jmb.2011.09.028).
31. Emsley P, Cowtan K. Coot: model-building tools for molecular graphics. *Acta Crystallogr D Biol Crystallogr*. 2004;60(12):2126. doi: [10.1107/S0907444904019158](https://doi.org/10.1107/S0907444904019158).
32. Murshudov GN, Vagin AA, Dodson EJ. Refinement of macromolecular structures by the maximum-likelihood method. *Acta Crystallogr D Biol Crystallogr*. 1997;53(3):240. doi: [10.1107/S0907444996012255](https://doi.org/10.1107/S0907444996012255).
33. Adams PD, Grosse-Kunstleve RW, Hung L-W, Ioerger TR, McCoy AJ, Moriarty NW, Read RJ, Sacchettini JC, Sauter NK, Terwilliger TC. PHENIX: building new software for automated crystallographic structure determination. *Acta Crystallogr D Biol Crystallogr*. 2002;58(11):1948–1954. doi: [10.1107/s0907444902016657](https://doi.org/10.1107/s0907444902016657).
34. Davis IW, Leaver-Fay A, Chen VB, Block JN, Kapral GJ, Wang X, Murray LW, Arendall WB, Snoeyink J, Richardson JS, et al. MolProbity: all-atom contacts and structure validation for proteins and nucleic acids. *Nucleic Acids Res*. 2007;35:W375–W383. doi: [10.1093/nar/gkm216](https://doi.org/10.1093/nar/gkm216).
35. DeLano WL. The PyMOL molecular graphics system. San Carlos (CA), USA: DeLano Scientific; 2002. <http://www.pymol.org>.
36. Hor L, Pilapitiya A, McKenna JA, Panjikar S, Anderson MA, Desvaux M, Paxman JJ, Heras B. Crystal structure of a subtilisin-like autotransporter passenger domain reveals insights into its cytotoxic function. *Nat Commun*. 2023;14(1):1163–1163. doi: [10.1038/s41467-023-36719-2](https://doi.org/10.1038/s41467-023-36719-2).
37. Beychok S. Circular dichroism of biological macromolecules. *Science*. 1966;154:1288–1299. doi: [10.1126/science.154.3754.1288](https://doi.org/10.1126/science.154.3754.1288).
38. Schindelin J, Arganda-Carreras I, Frise E, Kaynig V, Longair M, Pietzsch T, Preibisch S, Rueden C, Saalfeld S, Schmid B, et al. Fiji: an open-source platform for biological-image analysis. *Nat Methods*. 2012;9(7):676–682. doi: [10.1038/nmeth.2019](https://doi.org/10.1038/nmeth.2019).
39. Schuck P. Size-distribution analysis of macromolecules by sedimentation velocity ultracentrifugation and lamm equation modeling. *Biophys J*. 2000;78(3):1606–1619. doi: [10.1016/S0006-3495\(00\)76713-0](https://doi.org/10.1016/S0006-3495(00)76713-0).
40. Holm L, Kääriäinen S, Rosenström P, Schenkel A. Searching protein structure databases with DaliLite v.3. *Bioinformatics*. 2008;24(23):2780–2781. doi: [10.1093/bioinformatics/btn507](https://doi.org/10.1093/bioinformatics/btn507).
41. Domingo Meza-Aguilar J, Fromme P, Torres-Larios A, Mendoza-Hernández G, Hernandez-Chiñas U, Arreguin-Espinosa de Los Monteros RA, Eslava Campos CA, Fromme R. X-ray crystal structure of the passenger domain of plasmid encoded toxin(pet), an autotransporter enterotoxin from enteroaggregative

- Escherichia coli* (EAEC). *Biochem Biophys Res Commun.* **2014**;445(2):439–444. doi: [10.1016/j.bbrc.2014.02.016](https://doi.org/10.1016/j.bbrc.2014.02.016).
42. Otto BR, Sijbrandi R, Luirink J, Oudega B, Heddle JG, Mizutani K, Park S-Y, Tame JRH. Crystal structure of hemoglobin protease, a heme binding autotransporter protein from pathogenic *Escherichia coli*. *J Biol Chem.* **2005**;280(17):17339–17345. doi: [10.1074/jbc.M412885200](https://doi.org/10.1074/jbc.M412885200).
 43. Navarro-Garcia F. Serine proteases autotransporter of enterobacteriaceae: structures, subdomains, motifs, functions, and targets. *Mol Microbiol.* **2023**;120:178–193. doi: [10.1111/mmi.15116](https://doi.org/10.1111/mmi.15116).
 44. Perona JJ, Craik CS. Structural basis of substrate specificity in the serine proteases. *Protein Sci.* **1995**;4:337–360. doi: [10.1002/pro.5560040301](https://doi.org/10.1002/pro.5560040301).
 45. Scheidig AJ, Hynes TR, Pelletier LA, Wells JA, Kossiakoff AA. Crystal structures of bovine chymotrypsin and trypsin complexed to the inhibitor domain of alzheimer's amyloid β -protein precursor (APPI) and basic pancreatic trypsin inhibitor (BPTI): engineering of inhibitors with altered specificities. *Protein Sci.* **1997**;6(9):1806–1824. doi: [10.1002/pro.5560060902](https://doi.org/10.1002/pro.5560060902).
 46. Tejada-Dominguez F, Huerta-Cantillo J, Chavez-Duenas L, Navarro-Garcia F, Sperandio V. A novel mechanism for protein delivery by the type 3 secretion system for extracellularly secreted proteins. *mBio.* **2017**;8(2). doi: [10.1128/mBio.00184-17](https://doi.org/10.1128/mBio.00184-17).
 47. Rothbaum RJ, Giannella RA, Partin JC. Diarrhea caused by adherent enteropathogenic *E. coli*. *The J Pediatrics.* **1982**;101(3):486. doi: [10.1016/s0022-3476\(82\)80105-4](https://doi.org/10.1016/s0022-3476(82)80105-4).
 48. Rothbaum RJ, Partin JC, Saalfeld K, McAdams AJ. An ultrastructural study of enteropathogenic *Escherichia coli* infection in human infants. *Ultrastruct Pathol.* **1983**;4(4):291–304. doi: [10.3109/01913128309140582](https://doi.org/10.3109/01913128309140582).
 49. Kenny B, Finlay BB. Protein secretion by enteropathogenic *Escherichia coli* is essential for transducing signals to epithelial cells. *Proc Natl Acad Sci USA.* **1995**;92(17):7991–7995. doi: [10.1073/pnas.92.17.7991](https://doi.org/10.1073/pnas.92.17.7991).
 50. Vidal JE, Navarro-García F. EspC translocation into epithelial cells by enteropathogenic *Escherichia coli* requires a concerted participation of type V and III secretion systems. *Cellular Microbiol.* **2008**;10(10):1975–1986. doi: [10.1111/j.1462-5822.2008.01181.x](https://doi.org/10.1111/j.1462-5822.2008.01181.x).
 51. Navarro-Garcia F, Serapio-Palacios A, Vidal JE, Salazar MI, Tapia-Pastrana G. EspC promotes epithelial cell detachment by enteropathogenic *Escherichia coli* via sequential cleavages of a cytoskeletal protein and then focal adhesion proteins. *Infect Immun.* **2014**;82:2255–2265. doi: [10.1128/iai.01386-13](https://doi.org/10.1128/iai.01386-13).
 52. Serapio-Palacios A, Navarro-Garcia F. EspC, an Autotransporter protein secreted by Enteropathogenic *Escherichia coli*, causes apoptosis and necrosis through caspase and calpain activation, including direct procaspase-3 cleavage. *mBio.* **2016**;7. doi: [10.1128/mBio.00479-16](https://doi.org/10.1128/mBio.00479-16).
 53. Vidal JE, Navarro-García F. Efficient translocation of EspC into epithelial cells depends on enteropathogenic *Escherichia coli* and host cell contact. *Infect Immun.* **2006**;74(4):2293–2303. doi: [10.1128/IAI.74.4.2293-2303.2006](https://doi.org/10.1128/IAI.74.4.2293-2303.2006).
 54. Canizalez-Roman A, Navarro-García F. Fodrin CaM-binding domain cleavage by pet from enteroaggregative *Escherichia coli* leads to actin cytoskeletal disruption. *Mol Microbiol.* **2003**;48:947–958. doi: [10.1046/j.1365-2958.2003.03492.x](https://doi.org/10.1046/j.1365-2958.2003.03492.x).
 55. Chua EG, Al-Hasani K, Scanlon M, Adler B, Sakellaris H. Determinants of proteolysis and cell-binding for the *Shigella flexneri* cytotoxin, SigA. *Curr Microbiol.* **2015**;71(5):613–617. doi: [10.1007/s00284-015-0893-8](https://doi.org/10.1007/s00284-015-0893-8).
 56. Navarro-Garcia F, Canizalez-Roman A, Vidal JE, Salazar MI. Intoxication of epithelial cells by plasmid-encoded toxin requires clathrin-mediated endocytosis. *Microbiol (Soc For Gener Microbiol).* **2007**;153(9):2828–2838. doi: [10.1099/mic.0.2007/007088-0](https://doi.org/10.1099/mic.0.2007/007088-0).
 57. Akopyan K, Edgren T, Wang-Edgren H, Rosqvist R, Fahlgren A, Wolf-Watz H, Fallman M. Translocation of surface-localized effectors in type III secretion. *Proc Natl Acad Sci USA.* **2011**;108(4):1639–1644. doi: [10.1073/pnas.1013888108](https://doi.org/10.1073/pnas.1013888108).
 58. Paxman JJ, Lo AW, Sullivan MJ, Panjikar S, Kuiper M, Whitten AE, Wang G, Luan C-H, Moriel DG, Tan L, et al. Unique structural features of a bacterial autotransporter adhesin suggest mechanisms for interaction with host macromolecules. *Nat Commun.* **2019**;10(1):1967. doi: [10.1038/s41467-019-09814-6](https://doi.org/10.1038/s41467-019-09814-6).
 59. Heras B, Totsika M, Peters KM, Paxman JJ, Gee CL, Jarrott RJ, Perugini MA, Whitten AE, Schembri MA. The antigen 43 structure reveals a molecular velcro-like mechanism of autotransporter-mediated bacterial clumping. *Proc Natl Acad Sci USA.* **2014**;111:457–462. doi: [10.1073/pnas.1311592111](https://doi.org/10.1073/pnas.1311592111).